Our results indicate that BRCA1 deficiency caused by somatic mutation or promoter methylation of BRCA1 in sporadic ER-negative breast cancers sensitizes tumor cells to endogenous estrogen activating EMT, promoting CSCs and, therefore, inducing tumor progression. The gene discussed is BRCA1; the disease is neoplasm.